Smaller drugmakers have a more difficult time with clinical trial transparency than larger drugmakers, according to a study published July 19 in The BMJ.
The researchers examined 40 novel drugs and 22 biologics approved in 2016 and 2017. The 62 treatments were produced by 42 drugmakers. The research team analyzed each drugmakers’ practices regarding trial registration, results reporting, publication, FDA Amendments Act compliance and patient-level data sharing.
Below are the seven drugmakers that were tied for the top spot as the most transparent drugmakers:
- AbbVie
- Amgen
- Bayer
- Merck KGaA
- Novartis
- Roche/Genentech
- Takeda
